Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage

European Journal of Pharmacology

Volumn 458, Issue 1-2, 2003, Pages 81-89

  Takahata, Kazue ^a   Katsuki, Hiroshi ^b   Kobayashi, Yutaka ^a   Muraoka, Shizuko ^a   Yoneda, Fumio ^a   Kume, Toshiaki ^b   Kashii, Satoshi ^b   Honda, Yoshihito ^b   Akaike, Akinori ^b  

^a Fujimoto Pharmaceutical Corporation   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

BDNF (brain derived neurotrophic factor); Cell death; Desmethylselegiline; NMDA (N methyl D aspartate); Retinal degeneration; Selegiline

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DRUG METABOLITE; N METHYL DEXTRO ASPARTIC ACID; NORSELEGILINE; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL LABELING; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; MALE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA CELL; RETINA INJURY;

AMPHETAMINES; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DIZOCILPINE MALEATE; INJECTIONS; INJECTIONS, SUBCUTANEOUS; MALE; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RETINA; SELEGILINE; SUPERIOR COLLICULUS; VITREOUS BODY;

EID: 12244295160     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02729-2     Document Type: Article

References (40)

1. Amenta F., Bograni S., Cadel S., Ferrante F., Valsecchi B., Vega J.A. Microanatomical changes in the frontal cortex of aged rats: effect of L-deprenyl treatment. Brain Res. Bull. 34:1994;125-131.
2. Ansari K.S., Yu P.H., Kruck T.P.A., Tatton W.G. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J. Neurosci. 13:1993;4042-4053.
3. Arriba A.F., Lizcano J.M., Balsa D., Unzeta M. Contribution of different amine oxidases to the metabolism of dopamine in bovine retina. Biochem. Pharmacol. 42:1991;2355-2361.
4. Barber A.J., Paterson I.A., Gelowitz D.L., Voll C.L. Deprenyl protects rat hippocampal pyramidal cells from ischaemic insult. Soc. Neurosci. Abstr. 19:1993;1646.
5. Birkmayer W., Knoll J., Riederer P., Youdim M.B.H., Hars V., Marton J. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: a longterm study. J. Neural Transm. 64:1985;113-127.
6. Buys Y.M., Trope G.E., Tatton W.G. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr. Eye Res. 14:1995;119-126.
7. Carmignoto G., Maffei L., Candeo P., Canella R., Comelli C. Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J. Neurosci. 9:1989;1263-1272.
8. Carrillo M.-C., Kanai S., Nokubo M., Ivy G.O., Sato Y., Kitani K. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp. Neurol. 116:1992;286-294.
9. Choi D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11:1988;465-469.
10. Delbarre G., Delbarre B., Calinon F., Ferger A. Accumulation of amino acids and hydroxyl free radicals in brain and retina of gerbil after transient ischemia. J. Ocul. Pharmacol. 7:1991;147-155.
11. Heinonen E.H., Anttila M.I., Lammintausta R.A.S. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56:1994;742-749.
12. Honjo M., Tanihara H., Kido N., Inatani M., Okazaki K., Honda Y. Expression of ciliary neurotrophic factor activated by retinal Müller cells in eyes with NMDA- and kainic acid-induced neuronal death. Invest. Ophthalmol. Vis. Sci. 41:2000;552-560.
13. Kashii S., Takahashi M., Mandai M., Shimizu H., Honda Y., Sasa M., Ujihara H., Tamura Y., Yokota T., Akaike A. Protective action of dopamine against glutamate neurotoxicity in the retina. Invest. Ophthalmol. Vis. Sci. 35:1994;685-695.
14. Kido N., Tanihara H., Honjo M., Inatani M., Tatsuno T., Nakayama C., Honda Y. Neuroprotective effects of brain-derived neurotrophic factor in eyes with NMDA-induced neuronal death. Brain Res. 884:2000;59-67.
15. Ko M.-L., Hu D.-N., Ritch R., Sharma S.C. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41:2000;2967-2971.
16. Kristián T., Siesjö B.K. Calcium in ischemic cell death. Stroke. 29:1998;705-718.
17. Lucas D.R., Newhouse J.P. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch. Ophthalmol. 58:1957;193-201.
18. Ma Y.-T., Hsieh T., Forbes M.E., Johnson J.E., Frost D.O. BDNF injected into the superior colliculus reduces developmental retinal ganglion cell death. J. Neurosci. 18:1998;2097-2107.
19. Mansour-Robaey S., Clarke D.B., Wang Y.-C., Bray G.M., Aguayo A.J. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc. Natl. Acad. Sci. U.S.A. 91:1994;1632-1636.
20. Melega W.P., Cho A.K., Schmitz D., Kuczenski R., Segal D.S. L-Methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived L-methamphetamine. J. Pharmacol. Exp. Ther. 288:1999;752-758.
21. Mey J., Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res. 602:1993;304-317.
22. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., Hayashi K., Kuno S. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 279:2000;751-755.
23. ω-nitro-L-arginine methyl ester protects retinal neurons against N-methyl-D-aspartate-induced neurotoxicity in vivo. Eur. J. Pharmacol. 328:1997;45-49.
24. Mytilineou C., Radcliffe P., Leonardi E.K., Werner P., Olanow C.W. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68:1997;33-39.
25. Mytilineou C., Radcliffe P.M., Olanow C.W. L-(-)-Desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J. Neurochem. 68:1997;434-436.
26. Mytilineou C., Leonardi E.K., Radcliffe P., Heinonen E.H., Han S.-K., Werner P., Cohen G., Olanow C.W. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J. Pharmcol. Exp. Ther. 284:1998;700-706.
27. Nitta A., Ohmiya M., Jin-Nouchi T., Sometani A., Asami T., Kinukawa H., Fukumitsu H., Nomoto H., Furukawa S. Endogenous neurotrophin-3 is retrogradely transported in the rat sciatic nerve. Neuroscience. 88:1999;679-685.
28. Perry V.H. Evidence for an amacrine cell system in the ganglion cell layer of the rat retina. Neuroscience. 6:1981;931-944.
29. Ragaiey T., Ma J.-X., Jiang W.-J., Greene W., Seigel G.M., Stewart W.C. L-Deprenyl protects injured retinal precursor cells in vitro. J. Ocul. Pharmacol. 13:1997;479-488.
30. Sagot Y., Dubois-Dauphin M., Tan S.A., de Bilbao F., Aebischer P., Martinou J.C., Kato A.C. Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. J. Neurosci. 15:1995;7727-7733.
31. Sawada A., Neufeld A.H. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp. Eye Res. 69:1999;525-531.
32. Seniuk N.A., Henderson J.T., Tatton W.G., Roder J.C. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J. Neurosci. Res. 37:1994;278-286.
33. Tatton W.G. Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma. Eur. J. Ophthalmol. 9:1999;S22-S29.
34. Tatton W.G., Chalmers-Redman R.M.E. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 47(Suppl. 3):1996;S171-S183.
35. Tatton W.G., Ju W.Y.H., Wadia J., Tatton N.A. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. Olanow C.W., Jenner P., Youdin M. Neurodegeneration and Neuroprotection in Parkinson's disease. 1996;209-220 Academic Press, London.
36. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1989;1364-1371.
37. Trope G.E., Williams-Lyn D.E., Flanagan J.G., Buys Y., Tatton W.G. (-)Deprenyl improves visual function in glaucoma patients. Invest. Ophtalmol. Vis. Sci. 35 (Suppl.):1994;2178.
38. Vecino E., Ugarta M., Nash M.S., Osborne N.N. NMDA induces BDNF expression in the albino rat retina in vivo. NeuroReport. 10:1999;1103-1106.
39. Xu L., Ma J., Seigel G.M., Ma J.-X. L-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons. Biochem. Pharmacol. 58:1999;1183-1190.
40. Yoles E., Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch. Ophthalmol. 116:1998;906-910.